Anti-fibrotic effect of PF2401-SF, a standardized fraction of Salvia miltiorrhiza, in thioacetamide-induced experimental rats liver fibrosis

Archives of Pharmacal Research

Volumn 38, Issue 4, 2015, Pages 549-555

  Parajuli, Daya Ram ^a   Zhao, Yu Zhe ^a   Jin, Hao ^a   Chi, Jin Hua ^a   Li, Si Yuan ^a   Kim, Youn Chul ^a   Sohn, Dong Hwan ^a   Lee, Sung Hee ^a  

^a Wonkwang University   (South Korea)

Author keywords

Collagen 1( ); Fibrosis; Hepatic stellate cells; Salvia miltiorrhiza; Thioacetamide; Tissue inhibitor of metalloproteinase 1

Indexed keywords

HERBACEOUS AGENT; PF2401-SF; PLANT EXTRACT; THIOACETAMIDE;

ANIMAL; CHEMICALLY INDUCED; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; MALE; METABOLISM; RAT; SALVIA MILTIORRHIZA; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; DRUGS, CHINESE HERBAL; LIVER CIRRHOSIS; MALE; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SALVIA MILTIORRHIZA; THIOACETAMIDE; TREATMENT OUTCOME;

EID: 84939877151     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0425-2     Document Type: Article

References (34)

1. Bataller, R., and D.A. Brenner. 2005. Liver fibrosis. The Journal of clinical investigation 115: 209-218.
2. Benyon, R.C., J.P. Iredale, S. Goddard, P.J. Winwood, and M.J. Athur. 1996. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110: 821-831.
3. Bruck, R., R. Schey, H. Aeed, A. Hochman, O. Genina, and M. Pines. 2004. Protective effect of pyrrolidine dithiocarbamate in a rat model of liver cirrhosis. Liver International 24: 169-176.
4. Elsharkawy, A.M., F. Oakley, and D.A. Mann. 2005. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 10: 927-939.
5. Fallowfield, J.A., M. Mizuno, T.J. Kendall, C.M. Constandinou, R.C. Benyon, J.S. Duffield, and J.P. Iredale. 2007. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. The Journal of Immunology 178: 5288-5295.
6. Friedman, S.L. 1993. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. New England Journal of Medicine 328: 1828-1835.
7. Friedman, S.L. 2004. Mechanisms of hepatic fibrosis and therapeutic implications. Nature Clinical Practice Gastroenterology & Hepatology 1: 98-105.
8. Friedman, S.L. 2008. Mechanisms of hepatic fibrosis. Gastroenterology 134: 1665-1669.
9. Galli, A., G. Svegliati-Baroni, E. Ceni, S. Milani, F. Ridolfi, R. Salzano, M. Tarocchi, C. Grappone, G. Pellegrini, A. Benedetti, C. Surrenti, and A. Casini. 2005. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 41: 1074-1084.
10. Honda, H., K. Ikejima, M. Hirose, M. Yoshikawa, T. Lang, N. Enomoto, T. Kitmura, Y. Takei, and N. Sato. 2002. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 36: 12-21.
11. Hsu, Y.C., Y.L. Lin, Y.T. Chiu, M.S. Shiao, C.Y. Lee, and Y.T. Huang. 2005. Antifibrotic effects of Salvia miltiorrhiza on dimethylnitorsamine-intoxicated rats. Journal of Biomedical Science 12: 185-195.
12. Iredale, J.P. 2003. Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 327: 143-147.
13. Iredale, J.P. 2007. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. Journal of Clinical Investigation 3: 539-548.
14. Iredale, J.P., R.C. Benyon, J. Pickering, M. McCullen, M. Northrop, S. Pawley, C. Hovell, and M.J. Arthur. 1998. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. Journal of Clinical Investigation 102: 538-549.
15. Lee, T.Y., H.H. Chang, G.J. Wang, J.H. Chiu, Y.Y. Yang, and H.C. Lin. 2006. Water-soluble extract of Salvia miltiorrhiza ameliorates carbon tetrachloride-mediated hepatic apoptosis in rats. Journal of Pharmacy and Pharmacology 58: 659-665.
16. Li, G.S., W.L. Jiang, J.W. Tian, G.W. Qu, H.B. Zhu, and F.H. Fu. 2010. In vitro and In vivo antifibrotic effects of rosmarinic acid on experimental liver fibrosis. Phytomedicine 17: 282-288.
17. Lin, H.J., J.Y. Chen, C.F. Lin, S.T. Kako, J.C. Cheng, H.L. Chen, and C.M. Chen. 2011. Hepatoprotective effects of Yi Guan Jian, an herbal medicine, in rats with dimethylnitrosamine-induced liver fibrosis. Journal of Ethnopharmacology 134: 953-960.
18. Low, T.Y., C.K. Leow, M. Salto-Tellez, and M.C. Chung. 2004. A proteomic analysis of thioacetamide induced hepatotoxicity and cirrhosis in rat livers. Proteomics 12: 3960-3974.
19. Luedde, T., and R.F. Schwabe. 2011. NF-kB in the liver-linking injury, fibrosis and hepatocellular carcinoma. Nature reviews Gastroenterology & hepatology 8: 108-118.
20. Pallottini, V., C. Martini, A.M. Bassi, P. Romano, G. Nanni, and A. Trentalance. 2006. Rat HMG-CoA reductase activation in thioacetamide-induced liver injury is related to an increased reactive oxygen species content. Journal of Hepatology 44: 368-374.
21. Parajuli, D.R., E.J. Park, X.H. Che, W.Y. Jiang, Y.C. Kim, D.H. Sohn, and S.H. Lee. 2013. PF2401-SF, standardized fraction of Salvia miltiorrhiza, induces apoptosis of activated hepatic stelate cells in vitro and in vivo. Molecules 18: 2122-2134.
22. Park, E.J., Y.Z. Zhao, Y.C. Kim, and D.H. Sohn. 2007. PF2401-SF, standardized fraction of Salvia miltiorrhiza and its constituents, tanshinon I, tanshinone IIA, and cryptotansinone, protect primary cultured rat hepatocytes from bile acid-induced apoptosis by inhibiting JNK phosphorylation. Food and Chemical Toxicology 45: 1891-1898.
23. Park, E.J., Y.Z. Zhao, Y.C. Kim, and D.H. Sohn. 2009. Preventive effects of apurified extract isolated from Salvia miltiorrhiza enriched with tanshinone I, tanshinone IIA and cryptotanshinone on hepatocyte injury in vitro and vivo. Food and Chemical Toxicology 47: 2742-2748.
24. Parola, M., F. Marra, and M. Pinzani. 2008. Myofibroblast-like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Molecular Aspects of Medicine 29: 58-66.
25. Pinzani, M., M. Rosselli, and M. Zuckermann. 2011. Liver cirrhosis. Best Practice & Research Clinical Gastroenterology 25: 281-290.
26. Recknagel, R.O., E.A. Glende, J. Dolak, and R.L. Waller. 1989. Mechanism of carbon tetracholride toxicity. Pharmacology & Therapeutics 43: 139-154.
27. Rosenbloom, J., S.V. Castro, and S.A. Jimenez. 2010. Narrative review: Fibrotic diseases: Cellular and molecular mechanisms and novel therapies. Annals of Internal Medicine 3: 159-166.
28. Takahara, T., K. Furui, Y. Yata, B. Jin, L.P. Zhang, S. Nambu, H. Sato, M. Seiki, and A. Watanabe. 1997. Dual expression of matrix metalloproteinnase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers. Hepatology 26: 1521-1529.
29. Thyagarajan, S.P., S. Jayaram, V. Gopalakrishnan, R. Hari, P. Jayakumar, and M.S. Sripathi. 2002. Herbal medicines for liver diseases in India. Journal of Gastroenterology and Hepatology 17: 370-376.
30. Trebicka, J., M. Hennenberg, M. Odenthal, K. Shir, S. Klein, M. Granzow, A. Vogt, H.P. Dienes, F. Lammert, J. Reichen, J. Heller, and T. Sauerbruch. 2010. Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. Journal of Hepatology 4: 702-712.
31. Wang, C.H., T.H. Lee, C.N. Lu, W.Y. Chou, K.S. Hung, A.M. Concejero, and B. Jawan. 2006. Electroporative α-MSH gene transfer attenuates thioacetamide-induced murine hepatic fibrosis by MMP and TIMP modulation. Gene Therapy 13: 1000-1009.
32. Wasser, S., J.M. Ho, H.K. Ang, and C.E. Tan. 1998. Salvia miltiorrhiza reduces experimental - induced hepatic fibrosis in rats. Journal of Hepatology 29: 760-771.
33. Zhao, Z., Z. Liang, K. Chan, G. Lu, E.L. Lee, H. Chen, and L. Li. 2010. A unique issue in the standardization of Chinese materia medica: processing. Planta Medica 76: 1975-1986.
34. Zhou, L., Z. Zhu, and M.S. Chow. 2005. Danshen: an overview of its chemistry, pharmacology, pharmacokineics and clinical use. Journal of Clinical Pharmacology 45: 1345-1359.